The laboratory-created antibody, called IC14, binds to a human protein, CD14, found on the surface of immune cells.

Tuesday, April 13, 2021 NIAID Trial of Anti-CD14 Antibody to Treat COVID-19 Respiratory Disease Begins Transmission electron microscope image of SARS-CoV-2 emerging from human cells. Credit: NIAID NIAID has launched a clinical trial to test the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19. The laboratory-created antibody, called IC14, binds to a human protein, CD14, found on the surface of immune cells circulating in the blood and airway fluid and that also circulates as a stand-alone protein. CD14 helps immune cells recognize pathogens and injured or dying cells, alerting the immune system to danger and prompting it to respond. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107